InVivo halts trial of spine injury treatment after third patient dies

InVivo Therapeutics said Monday it has halted a trial of its spinal cord injury treatment after a third patient died, sending shares of the Cambridge company plummeting. InVivo (Nasdaq: NVIV) announced that it would temporarily stop enrolling patients in the trial of its Neuro-Spinal Scaffold, a biodegradable device invented in part by MIT professor Bob Langer designed to help patients heal after spinal cord injuries. The company said that the most recent patient to enroll in the study had died…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news